Profile
Marlies Sproll served as the Chief Scientific Officer at MorphoSys AG from 2000 to 2017.
Prior to that, she worked at Lanthio Pharma BV as a Member-Supervisory Board.
Dr. Sproll earned a doctorate degree from Max Planck Institute for Metals Research.
Former positions of Marlies Sproll
| Companies | Position | End |
|---|---|---|
| MORPHOSYS AG | Chief Tech/Sci/R&D Officer | 2017-04-14 |
Lanthio Pharma BV
 Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Director/Board Member | - |
Training of Marlies Sproll
| Max Planck Institute for Metals Research | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MORPHOSYS AG | Health Technology |
| Private companies | 1 |
|---|---|
Lanthio Pharma BV
Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Marlies Sproll
